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Population sequencing was performed for persons identi-
fied with persistent low-level viremia in 2 clinical trials.
Persistent low-level viremia (defined as plasma HIV-1 RNA
level .50 and ,1000 copies/mL in at least 2 determina-
tions over a 24-week period, after at least 24 weeks of
antiretroviral therapy) was observed in 65 (5.6%) of 1158
patients at risk. New resistance mutations were detected
during persistent low-level viremia in 37% of the 54
evaluable cases. The most common mutations were M184I/V
(14 cases), K103N (9), and M230L (3). Detection of new
mutations was associated with higher HIV-1 RNA levels
during persistent low-level viremia.
Persistent low-level viremia is associated with higher immune
activation [1], increased risk of virologic failure [1, 2], and
perhaps, increased mortality [3], compared with plasma HIV-1
RNA level ,50 copies/mL. Antiretroviral drug resistance during
low-level viremia is difficult to study because of the limitations
of conventional genotype testing. Studies of antiretroviral re-
sistance during low-level viremia have rarely addressed patients
receiving first-line antiretroviral therapy (ART) [4–8]. The
present study aimed to describe new resistance mutations in
patients with low-level viremia during first-line ART and to
evaluate the risk factors and virologic plus immunologic con-
sequences.
METHODS
Participants were identified retrospectively from 2 AIDS Clinical
Trials Group clinical trials: (1) all arms of A5142, which in-
cluded lopinavir-ritonavir plus efavirenz, lopinavir-ritonavir
plus 2 nucleos(t)ide reverse transcriptase inhibitors (NRTI), and
efavirenz plus 2 NRTIs [9], and (2) efavirenz-containing arms of
A5095, which included efavirenz plus lamivudine-zidovudine or
lamivudine-zidovudine-abacavir [10]. The NRTIs in A5142
were lamivudine plus zidovudine, stavudine, or tenofovir. The
present study was conducted with informed consent obtained
for A5142 and A5095.
Low-level viremia was defined as viral load (VL) .50 and
,1000 copies/mL in at least 2 determinations over a 24-week
period, after at least 24 weeks of ART. This definition included
participants who did not achieve VL ,50 copies/mL by week 24
and those who achieved VL ,50 copies/mL but subsequently
had viral rebound. The end of low-level viremia was defined as
the first VL #50 or $1000 copies/mL, unless it occurred within
a 6-month period during which at least 2 other VL determi-
nations met the low-level viremia definition (this was to account
for potential VL measurement error).
VL was determined using the ultrasensitive Roche Amplicor
HIV-1 Monitor assay (version 1.0 and/or 1.5). The study defi-
nition of low-level viremia falls within the approved range of this
assay. Pretreatment reverse transcriptase (RT) and protease (PR)
sequences were obtained from the parent study, or population
sequencing was performed on stored pretreatment plasma
samples when sequence data were not available. To detect mu-
tations during low-level viremia, the last plasma sample ob-
tained during low-level viremia was sequenced for all
participants. If any mutation was detected, the first sample ob-
tained during low-level viremia was sequenced; if there was
a discordance between the first and last samples, all the samples
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obtained during low-level viremia for that participant were se-
quenced. To enhance the sensitivity for detecting mutations at
low VL, ultracentrifugation of 1.5 mL of stored plasma was
performed to concentrate viral RNA (28,100 3g for 2 hours at
4C) before RNA extraction (QIAamp viral RNA minikit;
QIAGEN). HIV-1 PR (codons 1–99, HXB2 nucleotides
2254–2549) and RT (codons 1–234, HXB2 nucleotides
2550–3249) were reverse transcribed and amplified in a cou-
pled reverse transcription polymerase chain reaction (PCR;
40 cycles), followed by a 40-cycle nested-PCR using gene-
specific primers. Population sequencing was performed on
resulting purified amplicons with use of the Applied Bio-
systems Taq Dye Deoxy Terminator cycle sequencing kits,
which use a fluorescently labeled dideoxy-nucleotide chain
termination method, and resolved on an ABI 3730 automated
DNA sequencer (Applied Biosystems). Sequence processing
was done using the Sequencher program (Genecodes). Se-
quences were aligned to the HIV-1 subtype B reference strain
HXB2 (GenBank accession no. K03455). Each sample was
amplified in duplicate, and the amplicons were pooled for
analysis. Phylogenetic analysis using PhyML was used to
confirm sequence identity and to exclude PCR contamination.
The mutations of interest were any RT or major PR
mutation according to the International AIDS Society–USA
[11]. Analyses considered all mutations identified before
treatment and during low-level viremia. Risk factors for
developing low-level viremia were explored using Cox
proportional hazards, including all patients from A5142 and
A5095 with at least 48 weeks of follow-up; follow-up was
censored at initial treatment discontinuation. The assumption
of proportional hazards with respect to pretreatment co-
variates was evaluated with interaction terms with the natural
logarithm of time. Among patients with genotype available
before treatment and during low-level viremia, the distri-
butions of candidate risk factors were compared between
participants with new resistance mutations and those without
new resistance mutations with use of Wilcoxon rank sum and
Fisher’s exact tests; adjusted associations were examined using
logistic regression with exact methods as feasible. Sensitivity
analyses were conducted that excluded participants with
single VL outliers $1000 copies/mL during low-level viremia.
The immunologic consequences were evaluated using a nested
case-control study in which each low-level viremia case was
frequency matched with at least 1 control on the basis of
pretreatment VL (,100,000 or $100,000 copies/mL), pre-
treatment CD41 T-cell count (,200 or $200 cells/mm3), ran-
domized regimen, study, and race/ethnicity. Evaluation of
changes in immunologic parameters for case patients and con-
trol subjects used a paired analysis (Wilcoxon signed rank test) in
which the observed change during low-level viremia for each
case patient was compared with the mean change during the
same period in their set of matched control subjects.
RESULTS
Population With Low-level Viremia
Sixty-five (5.6%) of 1158 participants receiving initial ART in
A5142 (39 [7%] of 562) and A5095 (26 [4%] of 596) experi-
enced low-level viremia. These 65 participants received 2 NRTIs
plus efavirenz (31%), 2 NRTIs plus lopinavir-ritonavir (31%),
lopinavir-ritonavir plus efavirenz (22%), and 3 NRTIs plus
efavirenz (17%). Their median pretreatment VL was 5.1 log10
copies/mL, and median CD4 cell count was 121 cells/mm3.
Median time from treatment initiation to onset of low-level
viremia was 39 weeks (range, 25–119 weeks); median duration
was 30 weeks (range, 23–93 weeks). Forty-two participants
(68%) achieved VL ,50 copies/mL before onset of low-level
viremia. The median number of samples during low-level vire-
mia was 5 (range, 3–12).
Participants receiving 2 NRTIs plus lopinavir-ritonavir had an
estimated 2.7-fold greater hazard of low-level viremia (95%
confidence interval [CI], 1.4–5-fold), compared with partic-
ipants receiving 2 NRTIs plus efavirenz. Pretreatment VL $6
log10 copies/mL was associated with a 2.2-fold increased risk of
low-level viremia (95% CI, 1–4.6-fold). Each 50 cells/mm3 in-
crease in pretreatment CD4 cell count was associated with
a 10% lower hazard of low-level viremia (hazard ratio, .9; 95%
CI, 0.8–1.0). Associations with sex, age, race/ethnicity, and time-
updated recent adherence [12] were not detected (P . .15); no
violation of the proportional hazards assumption was detected
(P . .6).
New Resistance Mutations During Low-Level Viremia
Resistance data were available for 59 (91%) of 65 patients
with low-level viremia: 37 (95%) of 39 from A5142 and 22
(85%) of 26 from A5095. No plasma sample was available for
4 patients; 2 samples failed to amplify. Four participants had
pretreatment mutations in RT (K103N, V106I, G190A,
T215Y; V90I, V179D/V; V179D; and V108I) and 1 in PR
(M46I/M). Resistance data were available before treatment
and during low-level viremia for 54 participants. New re-
sistance mutations were detected during low-level viremia in
20 (37%) of these participants (Table 1), all in the RT region
except D30D/N in one participant. The most common mu-
tations were M184I/V (14 cases), K103N (9), and M230L (3).
Fourteen participants had new resistance mutations in the
first sample during low-level viremia; of these, 3 subsequently
accumulated additional mutations.
Among 39 participants who continued to receive their initial
regimen after low-level viremia, 65% of those with evidence and
74% of those without evidence of new resistance subsequently
achieved VL ,50 copies/mL at least once (P 5 .36). Two con-
secutive VL .1000 copies/mL after low-level viremia occurred
more frequently in participants with new mutations (30% vs
9%; P 5 .05).
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while on initial treatmentc
1 A5095 2NRTI 1 EFV 327 3.2 V90I, V179D/V M184V M230L/M 112 33 VF
2 A5142 2NRTI 1 LPV 636 4.7 ––– M184V ,50* 67 VF
3 A5095 2NRTI 1 EFV 37 4.8 ––– K101E, K103N, M184V M230L 76 58 VL ,50 copies/mL
4 A5095 2NRTI 1 EFV 373 4.6 K103N, V106I,
G190A T215Y
M184V (A62A/V) 101 32 Off treatment right after
low-level viremia
5 A5142 2NRTI 1 LPV 6 4.9 ––– V106M** 120 32 VL ,50 copies/mL and then VF
6 A5142 LPV/EFV 152 4.9 ––– K103N, M230L 105 72 VL ,50 copies/mL
7 A5142 2NRTI1EFV 192 5.3 ––– V106I 159 32 VL ,50 copies/mL
8 A5095 2NRTI1EFV 71 6.4 ––– M184V 8,322*** 144 Off treatment right after
low-level viremia
9 A5095 2NRTI1EFV 201 4.2 ––– Y188C (D67D/N) 203 96 VF
10 A5142 2NRTI1EFV 14 5.9 ––– K70K/R 105 33 Off treatment right after
low-level viremia
11 A5095 2NRTI1EFV 304 4.2 ––– K103N, M184V, G190A 494 26 One VL >1000 copies/mL and
one VL <50 copies/mL
12 A5095 3NRTI1EFV 284 4.1 ––– L74V, K103N, Y115F, M184V 368 111 Off treatment right after
low-level viremia
13 A5095 3NRTI1EFV 16 5.0 ––– K103N, M184V, P225H/P 238 32 One VL <50 copies/mL,
then low-level
viremia range
14 A5095 2NRTI1EFV 267 4.6 ––– K103N, M184V (V108I) 460 82 VF
15 A5142 2NRTI1LPV 74 4.8 ––– V75I 253 64 VL ,50 copies/mL*****
16 A5142 2NRTI1LPV 88 5.8 ––– M184V 362 80 No information available
17 A5095 3NRTI1EFV 52 6.0 ––– K103N, M184V (P225H) 417 48 VF*****
18 A5095 3NRTI1EFV 27 5.5 ––– K103N (M184V) 531 73 VF
19 A5142 2NRTI1LPV 212 4.2 ––– M 184V (D30D/N****) 383 49 Off treatment right after
low-level viremia
20 A5142 LPV/EFV 216 5.3 ––– Y181C/Y 57 31 VL ,50 copies/mL
NOTE. a First occurrence of RAM during low-level viremia (RAM that emerged later).
b Based on two consecutive measurements unless otherwise noted - VF: virologic failure (VL . 1,000 copies/mL).
c Time between randomized treatment initiation and collection of sample during low-level viremia.
* This sample was sequenced because M184V was detected in the last sample obtained during low-level viremia, but was not present in the first low-level viremia sample from this patient.
** No known exposure to an NNRTI.
*** VL measurements (copies/mL) in the 6 months around this measurement were 59, 57, 114, 8,322, and 963.
**** Only new resistance mutation in the protease gene.





















Factors Associated With New Mutations
Table 2 shows the distributions of candidate risk factors
for particpants with versus those without new mutations. VL
during low-level viremia was the primary factor associated with
new resistance. Participants in whom new mutations were
detected tended to have a higher VL at the start of low-level
viremia (P 5 .03) and higher minimum (P , .001), maximum
(P , .001), and mean VL during low-level viremia (P , .001).
There was also a suggestion that pretreatment VL was lower in
those with new resistance (median, 4.84 log10 vs 5.17 log10
copies/mL; P 5 .09). Similar results were seen in sensitivity
analyses. New mutations were detected in 0 (0%) of 10 partic-
ipants with maximum VL 51–100 copies/mL, compared with
5 (38%) of 13 with maximum VL 101–200 copies/mL and
Table 2. Association of Patient Parameters With New Resistance Detection During Low-Level Viremia (Includes Only Patients With








Age (years) Median 38 38.5 37.5 .40*
10%, 90% 31, 50 31, 50 26.0, 47.5
Sex Male 46 (85%) 30 (88%) 16 (80%) .45**
Female 8 (15%) 4 (12%) 4 (20%)
Race/ethnicity White non-Hispanic 18 (33%) 13 (38%) 5 (25%) .007**
Black non-Hispanic 21 (39%) 8 (24%) 13 (65%)
Hispanic (regardless
of race)
15 (28%) 13 (38%) 2 (10%)
Pretreatment VL (log10 copies/mL) Median 5.07 5.17 4.84 .09*
10%, 90% 4.22, 6.05 4.52, 6.05 4.13, 5.98
Pretreatment CD4 count (cells/mm3) Median 126 121 172 .44*
10%, 90% 16, 327 22, 295 15, 350
Length of low-level viremia (weeks) Median 32 33 27 .19*
10%, 90% 23, 56 24, 56 23, 45
First week of low-level viremia (week
on study)
Median 40 33 49 .19*
10%, 90% 31, 97 30, 97 32, 104
Number of outliers #50 copies/mL
in low-level viremia
0 26 (48%) 11 (32%) 15 (75%) .006**
1 26 (48%) 21 (62%) 5 (25%)
2 2 (4%) 2 (6%) 0 (0%)
Number of outliers $1000 copies/mL
in low-level viremia
0 45 (83%) 32 (94%) 13 (65%) .009**
1 9 (17%) 2 (6%) 7 (35%)
ART discontinuation . 7 days during
low-level viremia
No 50 (93%) 32 (94%) 18 (90%) .62**
Yes 4 (7%) 2 (6%) 2 (10%)
Adherence during low-level viremia ,100% 18 (33%) 9 (26%) 9 (45%) .23**
5100% 32 (59%) 23 (68%) 9 (45%)
Unknown 4 (7%) 2 (6%) 2 (10%)
First VL during low-level viremia
(copies/mL)
Median 113 90 181 .032*
10%, 90% 59, 383 58, 297 67, 400
Minimum VL during low-level viremia
(copies/mL)
Median 38 25 71 ,.001*
10%, 90% 25, 153 25, 72 25, 256
Maximum VL during low-level viremia
(copies/mL)
Median 282 150 615 .001*
10%, 90% 86, 1,476 80, 592 128, 7,589
Time adjusted area under the curve
(copies/mL)
Median 80 68 143 ,.001*
10%, 90% 53, 480 52, 137 69, 931
NOTE. *Exact Wilcoxon Test.
**Fisher’s Exact Test.
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15 (48%) of 31 with maximum VL .200 copies/mL. Attainment
of VL #50 copies/mL at any time during low-level viremia was
negatively associated with new mutations (P 5 .006), whereas
a VL increase to $1000 copies/mL was positively associated
(P 5 .009).
A larger proportion of participants with new mutations were
black, non-Hispanic (65% of participants with vs 24% of those
without new mutations; odds ratio, 4.2; 95% CI, 1.1–16.4).
Adjustment for maximum VL during low-level viremia atten-
uated this association, as did adjustment for mean VL. No as-
sociations between detection of new mutation and age, sex,
pretreatment CD4 cell count, attainment of VL ,50 copies/mL
before low-level viremia, or nonadherence before low-level vi-
remia were observed (P . .1).
Immunologic Consequences of Low-Level Viremia
No difference in CD4 cell count change over the low-level
viremia period between 64 case patients and the 64 sets of
matched control subjects was apparent (median difference,
216 cells/mm3; interquartile range [IQR], 279 to 49 cells/mm3;
P 5 .29). There were smaller changes in CD4 cell percentage
(median difference, 20.8; IQR, 23.7 to 1.3; P 5 .016) and in
CD4:CD8 ratio (median relative difference, 0.93; IQR, 0.73–1.06;
P , .001) in patients with low-level viremia.
DISCUSSION
This study explored new resistance mutations in patients
with low-level viremia during initial ART. Approximately
6% of patients who initiated lopinavir-ritonavir– or efavirenz-
containing ART developed low-level viremia. Pretreatment VL
$6 log10 copies/mL, lower pretreatment CD4 cell count, and
treatment with lopinavir-ritonavir were risk factors for low-
level viremia. The association between lopinavir-ritonavir and
low-level viremia as defined in this study is consistent with
previously observed slower viral suppression to ,50 copies/mL
with lopinavir-ritonavir–based regimens, compared with
efavirenz-based regimens [9]. New resistance mutations were
detected during low-level viremia in 37% of participants.
Higher levels of viremia during low-level viremia but not
higher pretreatment VL were associated with increased risk of
new mutations.
The association found between higher levels of viremia during
low-level viremia and increased risk of new resistance was
consistent when considering maximum, minimum, or mean VL.
New mutations were detected in some patients with maximum
observed VL ,200 copies/mL during low-level viremia, an
important observation considering recent guidelines that viro-
logic failure in clinical practice can be defined as VL .200
copies/mL [12]. Patients with isolated increases in VL to .1000
copies/mL were the most likely to have evidence of new re-
sistance. Participants with low-level viremia and new mutations
appeared to be at a higher risk for subsequent virologic
failure, but some patients with new mutations achieved viral
suppression without a change in regimen. Higher levels of
nonadherence and viremia not captured in the study possibly
influenced these findings. Different results might be obtained
using newer real-time PCR methods for VL measurement.
Mutations associated with resistance to lamivudine-
emtricitabine (M184V/I) and efavirenz-nevirapine (K103N)
were most frequently detected. The detection of etravirine
resistance–associated mutations in some patients receiving
efavirenz suggests that etravirine may not be fully active in
subsequent regimens. The only major protease inhibitor (PI)
mutation detected was the D30D/N. This participant was re-
ceiving lopinavir-ritonavir and had no known exposure to
nelfinavir. The mutation may represent a transmitted variant
not detected before treatment. Ritonavir-boosted PIs appear
to be likely to retain full activity in patients with low-level
viremia while receiving boosted PI-based first-line ART. Thy-
midine analogue mutations D67D/N and K70R were present
in 2 patients receiving thymidine analogues. Accordingly,
thymidine analogue activity may become occasionally com-
promised during low-level viremia. The L74V mutation was
detected in a patient receiving abacavir.
New mutations during low-level viremia appeared to be
more common in black (non-Hispanic) patients, but this
finding should be considered cautiously because of the small
number of events and the confounding effect of VL. An as-
sociation between African-American ethnicity and resistance
during low-level viremia has been reported previously, al-
though in a treatment-experienced population [5]. If con-
firmed, possible explanations could include differential
adherence [13] or race-based genetic factors that may in-
fluence drug metabolism and plasma concentrations [14].
In conclusion, new resistance mutations were detected in
patients experiencing low-level viremia during first-line ART.
Those with higher VL during low-level viremia had a greater
risk, but this association had limited precision. Techniques for
detecting resistance during low-level viremia should be validated
for clinical use, and the clinical consequences of low-level vire-
mia and mutations detected during low-level viremia should
be investigated further.
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